Product Images Rivastigmine Transdermal System
View Photos of Packaging, Labels & Appearance
- Label - lbl721621609
- Chemical Structure - rivastigmine 01
- Figure 1 - rivastigmine 02
- Figure 2 - rivastigmine 03
- Figure 3 - rivastigmine 04
- Figure 4 - rivastigmine 05
- Figure 5 - rivastigmine 06
- Figure 6 - rivastigmine 07
- Figure 7 - rivastigmine 08
- Figure 8 - rivastigmine 09
- Figure A - rivastigmine 10
- Figure B - rivastigmine 11
- Figure C - rivastigmine 12
- Figure D - rivastigmine 13
- Figure E - rivastigmine 14
- Figure F - rivastigmine 15
- Figure G - rivastigmine 16
- Figure H - rivastigmine 17
Product Label Images
The following 18 images provide visual information about the product associated with Rivastigmine Transdermal System NDC 72162-1609 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label - lbl721621609
Each patch of 10 cm2 contains 18 mg of Rivastigmine base with an in vivo release rate of 9.5 mg/24 hours. It is recommended to store the Transdermal System at 25°C (77°F) with excursions allowed between 15°C-30°C (59°F-86°F). This product is for transdermal use only and should be applied immediately after removal from the pouch. Be cautious not to use any patch that is damaged or shows signs of tampering. The package insert contains a QR code for dosage, administration, and discarding instructions.*
Chemical Structure - rivastigmine 01
Figure 1 - rivastigmine 02
Figure 2 - rivastigmine 03
Rivastigmine levels at various dosages of 13.3 mg/24 hours, 9.5 mg/24 hours, and 4.6 mg/24 hours with the corresponding number of participants in each group (n=19, n=22, n=22) were measured. The levels were found to be 20 ng/mL, 16 ng/mL, and 12 ng/mL respectively.*
Figure 3 - rivastigmine 04
This appears to be a report showing the least square means with standard error of the mean (SEM) for changes in ADAS-Cog ratings from baseline at 16 weeks during treatment. The data includes different dosages of medication and placebo, with labels indicating clinical improvement or decline.*
Figure 4 - rivastigmine 05
Figure 5 - rivastigmine 06
This text provides information about changes in ADCS-IADL scores from baseline, indicating clinical improvement and decline over time in a study comparing two different doses of Fivastomine Transdermal System (3.3 mg/24hr and 9.5 mg/24hr). The data is presented in a table showing the weeks of treatment.*
Figure 6 - rivastigmine 07
This text provides information about clinical improvement over weeks of treatment using ADAS-Cog change from baseline data. It appears to be a chart or graph displaying data points at various time intervals.*
Figure 7 - rivastigmine 08
Figure 8 - rivastigmine 09
Figure A - rivastigmine 10
Protective liners for Rivastigmine Transdermal System pouch. These liners help protect the medication pouch and provide added security during storage and use. Ideal for keeping the medication patch safe and secure.*
Figure B - rivastigmine 11
This text appears to be a list of body parts where a specific action or treatment might occur. It mentions parts like the upper arm, side of the chest, upper back, and lower back on either the left or right side. This could be referencing locations for procedures, assessments, or exercises related to these areas of the body.*
Figure C - rivastigmine 12
Figure D - rivastigmine 13
Figure E - rivastigmine 14
Figure F - rivastigmine 15
Figure G - rivastigmine 16
Figure H - rivastigmine 17
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
